Dublin, May 11, 2018 (GLOBE NEWSWIRE) -- The "HIV Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

• B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
• TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
• HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
• Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
• B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.

Key Topics Covered:

Forecast: HIV

• Overview
• Executive Summary
• Market Dynamics
• Forecast And Future Trends
• Market Definition And Methodology
• Primary Research Methodology
• Bibliography
• Product Profile: Atripla
• Product Profile (Late Stage): B/F/Taf
• Product Profile: Complera
• Product Profile (Late Stage): Dor/3Tc/Tdf
• Product Profile: Descovy
• Product Profile: Genvoya
• Product Profile: Isentress
• Product Profile: Juluca
• Product Profile: Odefsey
• Product Profile: Prezista Franchise
• Product Profile: Reyataz Franchise
• Product Profile: Stribild
• Product Profile: Symtuza
• Product Profile: Tivicay
• Product Profile (Late Stage): Tivicay/Epivir
• Product Profile: Triumeq
• Product Profile: Truvada
• Product Profile (Late Stage): Cabotegravir/Rilpivirine
• Product Profile (Late Stage): Fostemsavir

Treatment: HIV

• Overview
• Primary Research Methodology
• Disease Definition And Diagnosis
• Patient Segmentation
• Current Treatment Options
• Treatment Guidelines
• Prescribing Trends
• Unmet Needs In HIV
• Impact Of Generics

Epidemiology: HIV

• Overview
• Executive Summary
• Disease Background
• Sources And Methodology
• Forecast: HIV
• Epidemiologist Insight
• Strengths And Limitations
• Appendix: Additional Sources
• Bibliography

Marketed Drugs: HIV

• Overview
• Executive Summary
• Product Overview
• Product Profile: Atripla
• Product Profile: Complera
• Product Profile: Descovy
• Product Profile: Genvoya
• Product Profile: Isentress
• Product Profile: Juluca
• Product Profile: Odefsey
• Product Profile: Prezista Franchise
• Product Profile: Reyataz Franchise
• Product Profile: Stribild
• Product Profile: Symtuza
• Product Profile: Tivicay
• Product Profile: Triumeq
• Product Profile: Truvada

Pipeline: HIV

• Overview
• Executive Summary
• Clinical Pipeline Overview
• Product Profile (Late Stage): B/F/Taf
• Product Profile (Late Stage): Dor/3Tc/Tdf
• Product Profile (Late Stage): Tivicay/Epivir
• Product Profile (Late Stage): Cabotegravir/Rilpivirine
• Product Profile (Late Stage): Fostemsavir

For more information about this report visit https://www.researchandmarkets.com/research/4zcdv3/global_hiv?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: HIV/AIDS Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.